Amended number of shares and votes in NeuroVive Pharmaceutical AB (publ)

Lund, Sweden, 29 March 2019 - NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF)today announced an increase of the number of shares and votes in NeuroVive of 22,594,467 as a result of a fully performed preferential rights issue, resolved by the Board of Directors on 10 December 2018 and approved at the Extraordinary General Meeting on 17 January 2019, and a conducted directed new issue of shares on 7 March 2019.

Today, the last trading day of the month, there are in total 185,952,591 shares and votes in NeuroVive Pharmaceutical AB. 

This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act (1991:980).The information was submitted for publication, through the agency of the contact person set out below, at 8.30 a.m. CET on 29 March 2019.

For more information please contact:
Catharina Johansson, CFO, IR & Communications
+46 (0)46-275 62 21, ir@neurovive.com

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@neurovive.com, www.neurovive.com
For news subscription, please visit http://www.neurovive.com/press-releases/subscription-page/ 

About NeuroVive 
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for genetic mitochondrial diseases and one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®). The R&D portfolio also consists of projects for genetic mitochondrial disorders, NASH and cancer. The company advances drugs for rare diseases through clinical development into the market, with or without partners. For projects for common indications the goal is out-licensing in the preclinical phase. A subset of compounds under NeuroVive’s NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber’s Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF). 

About Us

Abliva AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for chronic treatment of primary mitochondrial diseases and one project, in preparation for clinical trials (NV354), for treatment of primary mitochondrial diseases with Complex I deficiency. NeuroSTAT for traumatic brain injury (TBI) is ready to enter a clinical phase II efficacy study. The R&D portfolio also consists of early projects. Abliva’s ambition is to take drugs for primary mitochondrial diseases through clinical development and all the way to market, with or without partners. For the TBI and NASH projects the goal is to enter strategic partnerships. A subset of compounds under the NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber’s Hereditary Optic Neuropathy (LHON). Abliva is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).